InvestSMART

The Hydration Pharmaceuticals Company Limited (ASX:HPC)

ALERT: Price-sensitive ASX Announcement for HPC
Current share price for HPC : $0.004 0 (0%)+
Announcement
Release
15 Jun 2026 9:35AM
Price at Release
$0.004
Full Release
download
Summary
The Hydration Pharmaceuticals Company Limited, trading as Hydralyte USA, announced a capital raising initiative and changes in its board and management team. The company will raise AUD 392,000 through the issuance of 98 million new shares at AUD 0.004 per share, with an additional 49 million options exercisable at AUD 0.006, subject to shareholder approval. The funds will support sales momentum in the US and consolidate growth through e-commerce. Significant cost reductions are expected following the CEO's resignation, with board remuneration also reduced by 50%. Two new non-executive directors, George Karafotias and Nick Katiforis, have been appointed, replacing Adem Karafili and Joseph Constable. The company aims to achieve cash-flow break-even and is exploring mergers and acquisitions to scale its operations.
Key Points
  • Firm commitment to raise A$392k via placement of 98 million shares
  • Issue of 49 million options at an exercise price of A$0.006
  • Funds to support US sales momentum and e-commerce growth
  • CEO Oliver Baker resigns; will continue in a consultancy role
  • Appointment of George Karafotias and Nick Katiforis as Non-Executive Directors
  • Resignation of Non-Executive Chair Adem Karafili and Director Joseph Constable
  • Board remuneration reduced from A$243,000 to A$120,000 per annum
  • Company explores strategic M&A opportunities to add scale
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.